Dupilumab is a human monoclonal antibody marketed as Dupixent for multiple allergic and inflammatory diseases including atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, and COPD. It works by blocking IL-4/IL-13 signaling pathways via IL-4 receptor alpha antagonism. The drug is prescription-only and has received multiple indication expansions after initial U.S. approval in 2017.
Recent biosimilar and biologic developments included Health Canada approval of denosumab biosimilars, FDA review actions, and new licensing and commercialisation agreements. Other updates covered court, trial and reimbursement agenda decisions.
Novartis received EU approval for Rhapsido (remibrutinib) as the first oral targeted treatment for chronic spontaneous urticaria. Phase 3 data also showed significant efficacy in chronic inducible urticaria, with filings underway for additional indications.
Atopic dermatitis updates in 2026 included long-term upadacitinib safety, phase 3 amlitelimab and rademikibart data, and 5-year interim dupilumab results in children. A market report also listed multiple emerging therapies in late-stage development.
Researchers at Icahn School of Medicine at Mount Sinai found that major depressive disorder shares key immune abnormalities with atopic dermatitis, particularly Th2 pathway activation. The team plans to test dupilumab in a clinical trial for depression.
Drug Hunter's most-accessed resources, reviews, and case studies in 2025 reflected key trends in drug discovery, including the rise of oral macrocycles, advances in new modalities, and the shift from biologics to small molecules in immunology.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07587658 |
This After Market Study is Seeing if Dupilumab Plus Usual Standard of Care (SOC) is Better Than Usual Care Alone for Adult Participants After a Severe Chronic Obstructive Pulmonary Disease (COPD) Flare-Up Requiring Hospitalization |
NOT_YET_RECRUITING | PHASE4 |
| NCT07574294 |
Dual REmission in Moderate-to-SEvere asthMa and Nasal Polyps |
COMPLETED | |
| NCT07467564 |
The Impact of Dupilumab Treatment on Anxiety and Depression Symptoms in Patients With Moderate-to-Severe Atopic Dermatitis |
RECRUITING | |
| NCT07448363 |
Atopic Dermatitis Treated With Dupilumab and JAK Inhibitors in Costa Rica |
NOT_YET_RECRUITING | |
| NCT07399067 |
A Proof-of-Concept Study of IBI3002 in Patients With Moderate to Severe Atopic Dermatitis |
RECRUITING | PHASE2 |
| NCT07352566 |
Utilization of a Microdevice for Psoriasis and Atopic Dermatitis |
NOT_YET_RECRUITING | PHASE4 |
| NCT07330934 |
A Study to Evaluate Efficacy and Safety of IBI356 in Participants With Moderate to Severe Atopic Dermatitis |
RECRUITING | PHASE2 |
| NCT07316114 |
A Study to Describe the Real-world Effectiveness, Safety and Patterns of Use of Dupilumab in Patients With Chronic Spontaneous Urticaria |
RECRUITING | |
| NCT07277322 |
Neoadjuvant Dupilumab and Toripalimab in MSS CRC Subjects With Resectable Liver Metastases |
NOT_YET_RECRUITING | PHASE1/PHASE2 |
| NCT07276425 |
Early and Long-Term Efficacy and Immune Changes With Dupilumab in Prurigo Nodularis |
RECRUITING |
